Relationship between thyroglobulin and tumor detectability with Thallium-201 in differentiated thyroid cancer;Beziehung zwischen thyreoglobulin und der treffsicherheit der Thallium- 201-szintigraphie differenzierter schilddrusenkarzinome

NuklearMedizin

Volumn 39, Issue 1, 2000, Pages 10-15

  Brandt Mainz, Katja ^a   Muller S P ^a   Reiners, Ch ^b   Bockisch, A ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Differentiated thyroid cancer; ROC analysis; Thallium 201 scintigraphy; Thyroglobulin

Indexed keywords

THALLIUM 201; THYROGLOBULIN; THYROTROPIN;

ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HUMAN; MAJOR CLINICAL STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID CANCER; THYROID SCINTISCANNING; TUMOR SCINTISCANNING;

EID: 0343729375     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1632238     Document Type: Article

References (33)

1. Arbab AS, Koizumi K, Toyama K, Araki T. Uptake of technetium-99m-tetrofosmin, technetium-99m-MIBI and thallium-201 in tumor cell lines. J Nucl Med 1996; 37: 1551-6.
2. Batge B, Dralle H, Padberg B, von Herbay B, Schröder S. Histology and immunocyto-chemistry of differentiated thyroid carcinomas do not predict radioiodine uptake: a clinicomorphological study of 62 recurrent or metastatic tumors. Virchows Arch Pathol Anat Histopathol 1992; 421: 521-6.
3. Brandt-Mainz K, Müller SP, Sonnenschein W, Bockisch A. Technetium-99m-furifosmin in the follow-up of differentiated thyroid cancer. J Nucl Med 1998; 39: 1536-1541.
4. Brendel AJ, Guyot M, Jeandot R, Lefort G, Manciet G. Thallium-201 imaging in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1988; 29: 1515-20.
5. Briele B, Hotze A, Kropp J, Bockisch A., Overbeck B, Grünwald F, Kaiser W, Biersack HJ. Comparison of [201Tl] and [99mTc]-MIBI in the follow-up of differentiated thyroid carcinomas. Nuklearmedizin 1991; 30: 115-24.
6. Charkes ND, Vitti RA, Brooks K.Thallium-201 SPECT increase detectability of thyroid cancer metastases. J Nucl Med 1990; 31: 147-53.
7. Dadparvar S, Krishna L, Brady LW, Slizofski WJ, Brown SJ, Chevres A, Micaily, B. The role of iodine-131 and thallium-201 imaging and serum thyroglobulin in the management of differentiated thyroid carcinoma. Cancer 1993; 71: 3767-73.
8. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H. Follow-up of differentiated thyroid cancer: What is the value of FDG and Sestamibi in the diagnostic algorithm? Nuklearmedizin 1998; 37: 12-7.
9. 18FDG-Ganzkörper-PET bei differnzierten Schilddrüsenkarzinomen. Nuklearmedizin 1995; 34: 127-34.
10. Gallowitsch HJ, Kresnik E, Mikosch P, Pipam W, Gomez I, Lind P. Tc-99m-terofosmin scintigraphy: an alternative scitigraphic method for following up differentiated thyroid carcinoma - preleminary results. Nuklearmedizin 1996; 35: 230-5.
11. Görges R, Kahaly G, Müller-Brand J, Mäcke H, Walgenbach S, Bruns C, Andreas J, Brandt-Mainz K, Bockisch A. Untersuchungen zum Somatostatinrezeptor-Status bei nichtmedullären Schilddrüsenkarzinomen. Nuklearmedizin 1999; 38: 15-23.
12. Hanley JA. The robustness of the "binormal" assumptions used in fitting ROC curves. Med Decis Making 1988; 8: 197-203.
13. Hoefnagel CA, Delprat CC Marcuse HR, de Vijlder JJM. Role of thallium-201 total-body scintigraphy in follow-up of thyroid carcinoma. J Nucl Med 1986; 27: 1854-1857.
14. Hüfner M, Reiners C. Thyroglobulin and thyroglobulin antibodies in the follow-up of thyroid cancer and endemic goiter. In: Schilddrüse 1985. Pfannenstiel P, Emrich D, Weinheimer B (eds.) Stuttgart, New York: Georg Thieme 1987; 2-9.
15. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A national cancer data base report on 53,856 cases of thyroid carcinome treated in the U.S., 1985-1995. Cancer 1998; 83: 2638-48.
16. Iida Y, Hidaka A, Hatabu H, Kasagi K, Konishi J. Follow-up study of postoperative patients with thyroid cancer by thallium-201 scintigraphy and serum thyroglobulin measurement. J Nucl Med 1991; 32: 2098-2100.
17. Klain M, Maurea S, Lastoria S, Cuoclo A, Salvatore M. Technetium-99m-tetrofosmin imaging of differentiated mixed thyroid cancer. J Nucl Med 1995; 36: 2248-51.
18. Krishna L, Dapdavar S, Brady LW, Micaily B. Meihofer M, Slizofski WJ, Brown SJ, Chevres A, Roman R, Khan AS. Paradoxical changes in iodine-131 scintigraphic findings in advanced follicular thyroid cancer. J Nucl Med 1993; 34: 1574-6.
19. Kosuda S, Yokoyama H, Katayama M, Yokoyawa T, Kusano S, Yamamoto O. Technetium-99m tetrofosmin and technetium 99m sestamibi imaging of multiple metastases from differentiated thyroid carcinoma. Eur J Nucl Med 1995; 22: 1218-20.
20. Lin JD, Kao PF, Wenig HF, Lu WT, Huang MJ. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma. Eur J Nucl Med 1998; 25: 695-700.
21. Maheshwari YK, Hill CS, Haynie TP, Hichey RC, Samaan NA. 131-I therapy in differentiated thyroid carcinoma: MD Anderson Hospital experience. Cancer 1981; 47: 664-8.
22. Maxon HR, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well-differentiated thyroid cancer. Endocrin Metab Clin North Am 1990; 19: 685-718.
23. Metz CE. Some practical issues of experimental design and data in radiol ROC studies. Invest Radiol 1989; 24: 234-45.
24. Müller SP, Guth-Tougelidis B, Piotrowski B, Farahati J, Reiners C. T1-201 scintigraphy in the follow-up of eosinophilic thyroid carcinoma. [Abstract] J Nucl Med 1990; 31: 767.
25. Nakada K, Katoh C, Kanegae K, Tsukamoto E, Shiga T, Itoh K, Tamaki N. Thallium-201 scintigraphy to predict therapeutic outcome of iodine-131 therapy of metastatic thyroid carcinoma. J Nucl Med 1998; 39: 807-10.
26. static thyroid carcinoma. J Nucl Med 1999; 40: 963-7.
27. Ramanna L, Waxman A, Braunstein G. Thallium-201 scintigraphy in differentiated thyroid cancer: comparison with radioiodine scintigraphy and serum thyroglobulin determinations. J Nucl Med 1991; 32: 441-446.
28. Reiners Chr, Müller SP, Farahati J, Eising EG. SPECT and planar scintigraphy in diagnostic and follow-up of thyroid cancer. Exp Clin Endocrinol 1994; 102: 43-50.
29. Reynolds JC, Robbins J. The changing role of radioiodine in the management of differentiated thyroid cancer. Sem Nucl med 1997; 27: 152-64.
30. Salvatore M, Carrutu L, Porta E. Thallium-201 as a positive indicator for lung neoplasms: preleminary experiments. Radiology 1976, 121: 487-8.
31. Schäffer R, Rainers Chr. Reimann J, Börner W. Das onkozytäre Schilddrüsenkarzinom: Klinischpathologische Renaissance einer Tumorform? Tumordiagnostik 1983; 4: 161-8.
32. Sehweil AM, McKillop JH, Milroy R, Abdel-Dayem HM, Omar YT. Mechanism of Tl-201 uptake in tumors. Eur J Nucl Med 1989; 15: 376-9.
33. Yen TC, Lin HD, Lee CH, Chang SL, Yeh SH. The role of technetium-99m sestamibi wholebody scans in diagnosing metastatic Hurthle cell carcinoma of the thyroid gland after total thyroidectoniy: a comparison with iodine-131 and thallium-201. Eur J Nucl Med 1994; 21: 980-983.